PDCD1 and melanoma: For example, FixVac (BNT111), a nanoparticulate liposomal RNA (RNA-LPX) vaccine for intravenous administration developed by Ugur Sahin et al., has shown that it induces PD-1+ effector memory T cells in Phase I clinical trials for patients with advanced melanoma.